Fritextsökning
Artiklar per år
Innehållstyper
-
GSK pays 2.2 billion dollars to settle Zantac lawsuits
British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against the company in the U.S. that alleged its discontinued drug Zantac caused cancer.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understanding the mechanism has changed our view of human biology and evolution, says KI Professor András Simon.
-
Trenderna som väntar inom healthtech
Svensk healthtech står sig ”väldigt bra”. Det säger Peter Kjäll, näringspolitisk expert på Tech Sverige. Han staplar vilka trender som sannolikt kommer prägla sektorn framöver, men också vad som kan sätta krokben för utvecklingen.
-
Italian pharmaceutical company buys rights to immunotherapy from Sanofi
Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Överby Wernstedt is studying the processes that occur in the brain during a TBE infection and hopes to contribute to developing a treatment.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along for much of the journey and has experienced setbacks, but also huge discoveries. “It’s amazing when you succeed,” she says.
-
Obesity-drug pioneers win Lasker Award
This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “have revolutionised the treatment of obesity”. Among others, Novo Nordisk’s Lotte Bjerre Knudsen is honoured.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence intervals”, Anna Törner writes in a column.
-
Johan Pehrson takes over the responsibility for research policy in Sweden
The Liberals' party leader Johan Pehrson takes over the assignment as Minister for Education. This was announced by Prime Minister Ulf Kristersson (M) on Tuesday last week.
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
“We should avoid surgery if we can”
Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about role models, surgery and Sweden’s strengths and weaknesses in medical research.
-
What will be the next big hype after obesity? – An expert panel highlighted their top picks
What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major life science event in Lund.
-
Ingrid Lönnstedt: ”The confidence interval and its width”
Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.
-
Calliditas vd om uppköpet: ”Kul att bolaget blir kvar i Sverige”
Uppköpet av svenska bolaget för specialistläkemedel Calliditas fullföljs av japanska Asahi Kasei. Tanken är att Calliditas ska blir Asahis europeiska huvudkontor, berättar Calliditas vd Renée Aguiar-Lucander.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided to apply for delisting of the company´s share from Nasdaq Stockholm.
-
Uppköpsbudet fullföljs – Calliditas tas över av japanskt konglomerat
Japanska Asahi fullföljer budet på Calliditas Therapeutics efter att ha nått över 90 procent av aktieinnehavet. Calliditas styrelse har nu beslutat att ansöka om avnotering av bolaget från Nasdaq Stockholm.
-
Artificial intelligence in radiology – “Risk prediction is very exciting”
A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiology at Lund University, radiology is a field that is well suited to the technology.
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.
-
Danish biotech to buy struggling American oncology company
Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.